| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1039045325 |
| P356 | DOI | 10.1038/SJ.ONC.1210477 |
| P932 | PMC publication ID | 3021475 |
| P698 | PubMed publication ID | 17471238 |
| P5875 | ResearchGate publication ID | 6359292 |
| P2093 | author name string | M M Moasser | |
| P2860 | cites work | ErbB2 and ErbB3 receptors mediate inhibition of calcium-dependent chloride secretion in colonic epithelial cells | Q22010784 |
| ERBIN: a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor | Q22254439 | ||
| Involvement of chemokine receptors in breast cancer metastasis | Q24290909 | ||
| HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors | Q24297102 | ||
| Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin | Q24305421 | ||
| Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3 | Q24309266 | ||
| Structural determinants of the interaction between the erbB2 receptor and the Src homology 2 domain of Grb7 | Q24310358 | ||
| Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family | Q24314750 | ||
| Binding of Neu Differentiation Factor with the Extracellular Domain of Her2 and Her3 | Q24315647 | ||
| The protein kinase complement of the human genome | Q24324497 | ||
| Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors | Q24339400 | ||
| Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera | Q24595150 | ||
| The ErbB2 and ErbB3 receptors and their ligand, neuregulin-1, are essential for development of the sympathetic nervous system | Q24601534 | ||
| HER-2/neu is rate-limiting for ovarian cancer growth. Conditional depletion of HER-2/neu by ribozyme targeting. | Q54151898 | ||
| ErbB2 Activation of ESX gene expression | Q56706073 | ||
| Strain-dependent epithelial defects in mice lacking the EGF receptor | Q58326927 | ||
| Molecular Portraits and 70-Gene Prognosis Signature Are Preserved throughout the Metastatic Process of Breast Cancer | Q59565565 | ||
| ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways | Q64379568 | ||
| The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor | Q70094433 | ||
| The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity | Q70141373 | ||
| Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene a | Q71328758 | ||
| Direct and specific interaction of c-Src with Neu is involved in signaling by the epidermal growth factor receptor | Q71703153 | ||
| Ready to partner | Q73046119 | ||
| Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results | Q73169036 | ||
| Genetic alterations in ERBB2-amplified breast carcinomas | Q73347592 | ||
| Neuregulin-induced association of Sos Ras exchange protein with HER2(erbB2)/HER3(erbB3) receptor complexes in Schwann cells through a specific Grb2-HER2(erbB2) interaction | Q73430716 | ||
| Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress HER2/neu | Q73453082 | ||
| C-erbB2, p27 and G1/S aberrations in human primary breast cancer | Q73742383 | ||
| Neuregulin induces the rapid association of focal adhesion kinase with the erbB2-erbB3 receptor complex in schwann cells | Q73754429 | ||
| Elevated activity and expression of Src-family kinases in human breast carcinoma tissue versus matched non-tumor tissue | Q73790378 | ||
| Amplification and expression of genes from the 17q11 approximately q12 amplicon in breast cancer cells | Q74583103 | ||
| The pea3 subfamily ets genes are required for HER2/Neu-mediated mammary oncogenesis | Q77220150 | ||
| New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays | Q77220709 | ||
| C-Src activation by ErbB2 leads to attachment-independent growth of human breast epithelial cells | Q77293332 | ||
| The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast | Q78656284 | ||
| The HER2 I655V polymorphism and risk of breast cancer in women < age 40 years | Q79207497 | ||
| MUC4 expression correlates with poor prognosis in small-sized lung adenocarcinoma | Q79382615 | ||
| MUC4 is a novel prognostic factor of extrahepatic bile duct carcinoma | Q79954617 | ||
| Regulation of EGF receptor signaling in the fruitfly D. melanogaster and the nematode C. elegans | Q81353881 | ||
| HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients | Q83367544 | ||
| Effective intravenous therapy of murine pulmonary metastases with an oncolytic herpes virus expressing interleukin 12 | Q95825588 | ||
| Expression of the ERBB3 gene product in breast cancer | Q35994633 | ||
| Cooperation of the ErbB2 receptor and transforming growth factor beta in induction of migration and invasion in mammary epithelial cells | Q36017569 | ||
| erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification | Q36080272 | ||
| Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines | Q36080585 | ||
| The epidermal growth factor receptor family | Q36236606 | ||
| Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer | Q36443026 | ||
| neu/ERBB2 cooperates with p53-172H during mammary tumorigenesis in transgenic mice | Q36568624 | ||
| Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity | Q36612010 | ||
| Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma | Q36616556 | ||
| ERBB-2 overexpression confers PI 3' kinase-dependent invasion capacity on human mammary epithelial cells | Q36621254 | ||
| Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members | Q36643816 | ||
| Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas | Q36644476 | ||
| Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity | Q36644521 | ||
| ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor | Q36653753 | ||
| The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours. | Q36656902 | ||
| Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors | Q36668724 | ||
| A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor | Q24648517 | ||
| Phosphotyrosine interactome of the ErbB-receptor kinase family | Q24672516 | ||
| The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation | Q24678674 | ||
| Acetylation-mediated transcriptional activation of the ETS protein ER81 by p300, P/CAF, and HER2/Neu | Q24683893 | ||
| Common ERBB2 polymorphisms and risk of breast cancer in a white British population: a case-control study | Q24797594 | ||
| Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab | Q27640593 | ||
| The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors | Q27640631 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Untangling the ErbB signalling network | Q27860884 | ||
| Molecular portraits of human breast tumours | Q28032461 | ||
| The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy | Q28191663 | ||
| Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer | Q28203143 | ||
| An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors | Q28207289 | ||
| Heregulin-dependent activation of phosphoinositide 3-kinase and Akt via the ErbB2/ErbB3 co-receptor | Q28215701 | ||
| MLN64 and MENTHO, two mediators of endosomal cholesterol transport | Q28240973 | ||
| Severe neuropathies in mice with targeted mutations in the ErbB3 receptor | Q28251972 | ||
| Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesis | Q28281813 | ||
| Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2 | Q28283279 | ||
| Independent amplification and frequent co-amplification of three nonsyntenic regions on the long arm of chromosome 20 in human breast cancer | Q28287018 | ||
| Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas | Q28287906 | ||
| Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype | Q28509173 | ||
| Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor | Q28509287 | ||
| Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease | Q28570541 | ||
| An intramembrane modulator of the ErbB2 receptor tyrosine kinase that potentiates neuregulin signaling | Q28582768 | ||
| ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice | Q28590176 | ||
| Roles of mitogen-activated protein kinase and phosphoinositide 3'-kinase in ErbB2/ErbB3 coreceptor-mediated heregulin signaling | Q28678652 | ||
| ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer | Q28678776 | ||
| Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers | Q28679173 | ||
| Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer | Q29547699 | ||
| The phosphatidylinositol 3-Kinase AKT pathway in human cancer | Q29547860 | ||
| Cancer. Addiction to oncogenes--the Achilles heal of cancer | Q29614243 | ||
| The ErbB signaling network: receptor heterodimerization in development and cancer | Q29617919 | ||
| Src family kinases and HER2 interactions in human breast cancer cell growth and survival | Q30307291 | ||
| c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function | Q30442374 | ||
| HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder | Q36671182 | ||
| Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene | Q36851389 | ||
| ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization | Q37054834 | ||
| Mutations affecting conserved cysteine residues within the extracellular domain of Neu promote receptor dimerization and activation | Q37375814 | ||
| Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. | Q38291062 | ||
| Alternative intracellular routing of ErbB receptors may determine signaling potency | Q38337018 | ||
| The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast | Q38487693 | ||
| Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation | Q38669920 | ||
| Par6-aPKC uncouples ErbB2 induced disruption of polarized epithelial organization from proliferation control | Q40216411 | ||
| Controlled activation of ErbB1/ErbB2 heterodimers promote invasion of three-dimensional organized epithelia in an ErbB1-dependent manner: implications for progression of ErbB2-overexpressing tumors | Q40278717 | ||
| The mucin Muc4 potentiates neuregulin signaling by increasing the cell-surface populations of ErbB2 and ErbB3. | Q40281070 | ||
| ERBB2-mediated transcriptional up-regulation of the alpha5beta1 integrin fibronectin receptor promotes tumor cell survival under adverse conditions. | Q40296374 | ||
| FAK signaling is critical for ErbB-2/ErbB-3 receptor cooperation for oncogenic transformation and invasion | Q40353474 | ||
| The c-Src tyrosine kinase associates with the catalytic domain of ErbB-2: implications for ErbB-2 mediated signaling and transformation. | Q40371716 | ||
| Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. | Q40449400 | ||
| Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells. | Q40456753 | ||
| ErbB2 overexpression in mammary cells upregulates VEGF through the core promoter | Q40484060 | ||
| ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface | Q40540606 | ||
| Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. | Q40616262 | ||
| Switching off HER-2/neu in a tetracycline-controlled mouse tumor model leads to apoptosis and tumor-size-dependent remission. | Q40617423 | ||
| Polar expression of ErbB-2/HER2 in epithelia. Bimodal regulation by Lin-7. | Q40635663 | ||
| Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis: distribution of homo- and heterodimers depends on relative HER2 levels | Q40657210 | ||
| p38MAPK induces cell surface alpha4 integrin downregulation to facilitate erbB-2-mediated invasion | Q40661252 | ||
| PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest | Q40702262 | ||
| Correlation of p27 protein expression with HER-2/neu expression in breast cancer. | Q40713599 | ||
| Mammary glands reconstituted with Neu/ErbB2 transformed HC11 cells provide a novel orthotopic tumor model for testing anti-cancer agents | Q40778601 | ||
| Oncogenic signals of HER-2/neu in regulating the stability of the cyclin-dependent kinase inhibitor p27. | Q40872982 | ||
| Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes. | Q41062486 | ||
| Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3 (HER3) receptor protein | Q41120641 | ||
| Reversible tumorigenesis in mice by conditional expression of the HER2/c-erbB2 receptor tyrosine kinase. | Q41168882 | ||
| Requirement for neuregulin receptor erbB2 in neural and cardiac development | Q41269625 | ||
| Activation of Src family kinases in Neu-induced mammary tumors correlates with their association with distinct sets of tyrosine phosphorylated proteins in vivo. | Q41273163 | ||
| Nuclear localization of p185neu tyrosine kinase and its association with transcriptional transactivation | Q41441273 | ||
| Intracellular expression of single chain antibodies reverts ErbB-2 transformation. | Q41441346 | ||
| Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor | Q41606330 | ||
| Rescue of the cardiac defect in ErbB2 mutant mice reveals essential roles of ErbB2 in peripheral nervous system development | Q41678095 | ||
| Signal transduction by epidermal growth factor and heregulin via the kinase-deficient ErbB3 protein | Q42159151 | ||
| Amplification of a 280-Kilobase Core Region at the ERBB2 Locus Leads to Activation of Two Hypothetical Proteins in Breast Cancer | Q42249021 | ||
| Severe follicular hyperplasia and spontaneous papilloma formation in transgenic mice expressing the neu oncogene under the control of the bovine keratin 5 promoter | Q42451150 | ||
| Targeted expression of activated erbB-2 to the epidermis of transgenic mice elicits striking developmental abnormalities in the epidermis and hair follicles. | Q42454330 | ||
| Conditional expression of the ErbB2 oncogene elicits reversible hyperplasia in stratified epithelia and up-regulation of TGFalpha expression in transgenic mice | Q42473769 | ||
| Overexpression of ErbB2 impairs ligand-dependent downregulation of epidermal growth factor receptors via a post-transcriptional mechanism | Q42473794 | ||
| Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor development | Q42493129 | ||
| Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma | Q42510917 | ||
| Suppression of Neu-induced mammary tumor growth in cyclin D1 deficient mice is compensated for by cyclin E. | Q42668179 | ||
| Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts | Q42801594 | ||
| Heregulin and HER2 signaling selectively activates c-Src phosphorylation at tyrosine 215. | Q42801655 | ||
| Role of exon-16-deleted HER2 in breast carcinomas | Q42803579 | ||
| Cooperative signaling between alpha(6)beta(4) integrin and ErbB-2 receptor is required to promote phosphatidylinositol 3-kinase-dependent invasion | Q42803797 | ||
| erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells | Q42807469 | ||
| Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu | Q42807740 | ||
| Selective cleavage of the heregulin receptor ErbB-4 by protein kinase C activation | Q42810137 | ||
| Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. | Q42811529 | ||
| A hypoxia-independent hypoxia-inducible factor-1 activation pathway induced by phosphatidylinositol-3 kinase/Akt in HER2 overexpressing cells | Q42815891 | ||
| All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired | Q42816057 | ||
| Regulation of cyclooxygenase-2 pathway by HER2 receptor | Q42820225 | ||
| Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. | Q42823593 | ||
| A putative molecular-activation switch in the transmembrane domain of erbB2. | Q30476898 | ||
| HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review | Q30932448 | ||
| A data model to predict HER2 status in breast cancer based on the clinical and pathologic profiles of a large patient population at a single institution | Q33244281 | ||
| Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway | Q33884776 | ||
| ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling | Q33886341 | ||
| A strain-independent postnatal neurodegeneration in mice lacking the EGF receptor | Q33888193 | ||
| Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers | Q33888963 | ||
| Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer | Q33890758 | ||
| AKT plays a central role in tumorigenesis | Q33944165 | ||
| HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression | Q33968465 | ||
| Specific protection against breast cancers by cyclin D1 ablation | Q34082446 | ||
| PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization | Q34150579 | ||
| HER2-Mediated Effects on EGFR Endosomal Sorting: Analysis of Biophysical Mechanisms | Q34183239 | ||
| ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini | Q34187916 | ||
| The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification | Q34249785 | ||
| Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. | Q34250172 | ||
| The EGF receptor family as targets for cancer therapy | Q34293543 | ||
| Myc and mammary cancer: Myc is a downstream effector of the ErbB2 receptor tyrosine kinase | Q34316140 | ||
| Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells | Q34353519 | ||
| Lung cancer: intragenic ERBB2 kinase mutations in tumours | Q34354426 | ||
| Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis | Q34372081 | ||
| An overview of HER2. | Q34482977 | ||
| Upregulation of the Catalytic Telomerase Subunit by the Transcription Factor ER81 and Oncogenic HER2/Neu, Ras, or Raf. | Q34551813 | ||
| Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene | Q34560337 | ||
| PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling | Q35076033 | ||
| The epidermal growth factor system in Caenorhabditis elegans | Q35089332 | ||
| The role of the cyclin D1-dependent kinases in ErbB2-mediated breast cancer | Q35096122 | ||
| Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. | Q35112126 | ||
| Targeting the PI3K-Akt pathway in human cancer: rationale and promise | Q35571372 | ||
| The subcellular localization of the neu protein in human normal and neoplastic cells | Q35573517 | ||
| MUC4 expression is a novel prognostic factor in patients with invasive ductal carcinoma of the pancreas | Q35589094 | ||
| Loss of Hsp90 association up-regulates Src-dependent ErbB2 activity | Q35641650 | ||
| Biology of the epidermal growth factor receptor family. | Q35784977 | ||
| A mouse model for breast cancer induced by amplification and overexpression of the neu promoter and transgene | Q35943854 | ||
| A novel splice variant of HER2 with increased transformation activity | Q42824817 | ||
| p27 Kip1 inhibits HER2/neu-mediated cell growth and tumorigenesis | Q42827384 | ||
| Upregulation of IKKalpha/IKKbeta by integrin-linked kinase is required for HER2/neu-induced NF-kappaB antiapoptotic pathway | Q42830760 | ||
| NIH/3T3 cells transformed with the activated erbB-2 oncogene can be phenotypically reverted by a kinase deficient, dominant negative erbB-2 variant | Q42833659 | ||
| Alpha 6 beta 4 and alpha 6 beta 1 integrins associate with ErbB-2 in human carcinoma cell lines. | Q42834861 | ||
| Constitutive MEK/MAPK activation leads to p27(Kip1) deregulation and antiestrogen resistance in human breast cancer cells | Q43723448 | ||
| Loss of heterozygosity analysis in primary mammary tumors and lung metastases of MMTV-MTAg and MMTV-neu transgenic mice. | Q43767001 | ||
| Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene | Q44198914 | ||
| Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis | Q44259982 | ||
| Muc4/Sialomucin Complex, the Intramembrane ErbB2 Ligand, Translocates ErbB2 to the Apical Surface in Polarized Epithelial Cells | Q44441861 | ||
| A point mutation in the neu oncogene mimics ligand induction of receptor aggregation | Q44611984 | ||
| MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type | Q44749304 | ||
| Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification | Q44876355 | ||
| Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation | Q44907727 | ||
| Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma | Q44937760 | ||
| Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers | Q45121992 | ||
| Targeted disruption of ErbB2/Neu in the mammary epithelium results in impaired ductal outgrowth | Q45174160 | ||
| ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis | Q45309122 | ||
| HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice | Q45654401 | ||
| Elevated frequency of loss of heterozygosity in mammary tumors arising in mouse mammary tumor virus/neu transgenic mice | Q45749255 | ||
| Intracellular antibody against erbB-2 mediates targeted tumor cell eradication by apoptosis | Q45877626 | ||
| Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues | Q46076087 | ||
| Copy number aberrations in mouse breast tumors reveal loci and genes important in tumorigenic receptor tyrosine kinase signaling | Q46107577 | ||
| Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance | Q46469740 | ||
| Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients | Q46623138 | ||
| Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor | Q46766121 | ||
| Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer | Q48371008 | ||
| Amplification of a novel v-erbB-related gene in a human mammary carcinoma | Q48375434 | ||
| HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. | Q52035056 | ||
| Targeted expression of a dominant negative epidermal growth factor receptor in the mammary gland of transgenic mice inhibits pubertal mammary duct development. | Q52192094 | ||
| Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. | Q52572763 | ||
| The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen | Q52827123 | ||
| Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression. | Q52936283 | ||
| Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer. | Q53335960 | ||
| Prostatic intraepithelial neoplasia and adenocarcinoma in mice expressing a probasin-Neu oncogenic transgene. | Q53350536 | ||
| Effects of ErbB-2 overexpression on mitogenic signalling and cell cycle progression in human breast luminal epithelial cells. | Q53386780 | ||
| Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. | Q53412908 | ||
| Frequent induction of mammary carcinomas following neu oncogene transfer into in situ mammary epithelial cells of susceptible and resistant rat strains. | Q53495829 | ||
| Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein. | Q53513132 | ||
| HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry. | Q53597732 | ||
| Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. | Q53606400 | ||
| Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. | Q53645618 | ||
| Breast cancer risk factors and HER2 over-expression in tumors. | Q53667470 | ||
| P433 | issue | 45 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 6469-6487 | |
| P577 | publication date | 2007-04-30 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis | |
| P478 | volume | 26 |
| Q41835781 | (18)F-FDG PET/CT of advanced gastric carcinoma and association of HER2 expression with standardized uptake value |
| Q37414060 | A Comparative Performance Analysis of Multispectral and RGB Imaging on HER2 Status Evaluation for the Prediction of Breast Cancer Prognosis |
| Q53262757 | A feedback loop between BEX2 and ErbB2 mediated by c-Jun signaling in breast cancer. |
| Q37317542 | A new role of the Rac-GAP β2-chimaerin in cell adhesion reveals opposite functions in breast cancer initiation and tumor progression |
| Q55026505 | A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors. |
| Q38985097 | A novel Affibody bioconjugate for dual-modality imaging of ovarian cancer |
| Q38830205 | A novel dual EGFR/HER2 inhibitor KU004 induces cell cycle arrest and apoptosis in HER2-overexpressing cancer cells |
| Q28283309 | A requirement for Nedd9 in luminal progenitor cells prior to mammary tumorigenesis in MMTV-HER2/ErbB2 mice |
| Q54222781 | A significant subgroup of resectable gallbladder cancer patients has an HER2 positive status. |
| Q38886304 | ATM kinase sustains HER2 tumorigenicity in breast cancer |
| Q43917572 | Ablation of breast cancer cells using trastuzumab-functionalized multi-walled carbon nanotubes and trastuzumab-diphtheria toxin conjugate. |
| Q54986604 | Activating HER2 mutations as emerging targets in multiple solid cancers. |
| Q36902984 | Activating mutations and senescence secretome: new insights into HER2 activation, drug sensitivity and metastatic progression |
| Q33880386 | Activation of the unfolded protein response bypasses trastuzumab-mediated inhibition of the PI-3K pathway |
| Q37837267 | Added value of molecular targeted agents in oncology |
| Q53632731 | Addition of all-trans-retinoic acid to omeprazole and sucralfate therapy improves the prognosis of gastric dysplasia. |
| Q38954660 | Additive impact of HER2-/PTK6-RNAi on interactions with HER3 or IGF-1R leads to reduced breast cancer progression in vivo. |
| Q39045586 | Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities |
| Q93159538 | Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer |
| Q90777008 | Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia |
| Q47099768 | Alcohol and Cancer Stem Cells |
| Q48265569 | An Eighteen-Membered Macrocyclic Ligand for Actinium-225 Targeted Alpha Therapy |
| Q64232884 | Anti-tumor effect of neratinib against lung cancer cells harboring oncogene alterations |
| Q38932495 | Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer |
| Q58652190 | Application of Quantum Dots-Based Biotechnology in Cancer Diagnosis: Current Status and Future Perspectives |
| Q44885327 | Are biopsy specimens predictive of HER2 status in gastric cancer patients? |
| Q35831069 | Association between HER2 status in gastric cancer and clinicopathological features: a retrospective study using whole-tissue sections |
| Q54286036 | Association of ErbB1-4 expression in invasive breast cancer with clinicopathological characteristics and prognosis. |
| Q37648136 | Associations between pathologic tumor features and preadjuvant therapy cognitive performance in women diagnosed with breast cancer. |
| Q91592473 | Atovaquone: An Antiprotozoal Drug Suppresses Primary and Resistant Breast Tumor Growth by Inhibiting HER2/β-Catenin Signaling |
| Q34318275 | Autocrine motility factor promotes HER2 cleavage and signaling in breast cancer cells |
| Q39126208 | Autocrine/paracrine mechanism of interleukin-17B receptor promotes breast tumorigenesis through NF-κB-mediated antiapoptotic pathway |
| Q33578209 | BMP9 inhibits proliferation and metastasis of HER2-positive SK-BR-3 breast cancer cells through ERK1/2 and PI3K/AKT pathways |
| Q89406914 | Behavioral remodeling of normal and cancerous epithelial cell lines with differing invasion potential induced by substrate elastic modulus |
| Q99570496 | Beyond Chemotherapies: Recent Strategies in Breast Cancer Treatment |
| Q33652374 | Biochanin A Modulates Cell Viability, Invasion, and Growth Promoting Signaling Pathways in HER-2-Positive Breast Cancer Cells |
| Q34023695 | Biological subtypes of breast cancer: Prognostic and therapeutic implications |
| Q35496778 | Breast cancer medications and vision: effects of treatments for early-stage disease |
| Q49787807 | Breast cancer stem cells in HER2-negative breast cancer cells contribute to HER2-mediated radioresistance and molecular subtype conversion: clinical implications for serum HER2 in recurrent HER2-negative breast cancer |
| Q38120594 | C-erbB2/HER2 in human gliomas, medulloblastomas, and meningiomas: a minireview |
| Q36881905 | CDC25A protein stability represents a previously unrecognized target of HER2 signaling in human breast cancer: implication for a potential clinical relevance in trastuzumab treatment. |
| Q40950455 | CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion. |
| Q34810268 | Calmodulin binds HER2 and modulates HER2 signaling |
| Q92713095 | Can trastuzumab emtansine be replaced by additional chemotherapy plus targeted therapy for HER2-overexpressing breast cancer patients with residual disease after neoadjuvant chemotherapy? |
| Q34049715 | Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. |
| Q33638968 | Carnosine retards tumor growth in vivo in an NIH3T3-HER2/neu mouse model |
| Q21146639 | Cas proteins: dodgy scaffolding in breast cancer |
| Q92105345 | Cell-Free Co-Translational Approaches for Producing Mammalian Receptors: Expanding the Cell-Free Expression Toolbox Using Nanolipoproteins |
| Q28397579 | Cellular and molecular mechanisms underlying alcohol-induced aggressiveness of breast cancer |
| Q64055605 | Clinical development of targeted and immune based anti-cancer therapies |
| Q92782955 | Closer to Nature Through Dynamic Culture Systems |
| Q50145710 | Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy. |
| Q38811497 | Coexpressed Catalase Protects Chimeric Antigen Receptor-Redirected T Cells as well as Bystander Cells from Oxidative Stress-Induced Loss of Antitumor Activity. |
| Q90178692 | Concomitant use of renin-angiotensin-aldosterone system inhibitors prevent trastuzumab-induced cardiotoxicity in HER2+ breast cancer patients: an institutional retrospective study |
| Q42113818 | Contrast Enhancement on Cone-Beam Breast-CT for Discrimination of Breast Cancer Immunohistochemical Subtypes |
| Q89939813 | Contrast-Enhanced CT Parameters of Gastric Adenocarcinoma: Can Radiomic Features Be Surrogate Biomarkers for HER2 Over-Expression Status? |
| Q28728701 | Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer |
| Q64058529 | Crosstalks of the PTPIP51 interactome revealed in Her2 amplified breast cancer cells by the novel small molecule LDC3/Dynarrestin |
| Q61800494 | Cullin-3/KCTD10 E3 complex is essential for Rac1 activation through RhoB degradation in human epidermal growth factor receptor 2-positive breast cancer cells |
| Q33677510 | Cytogenetic and cDNA microarray expression analysis of MCF10 human breast cancer progression cell lines. |
| Q30352693 | Cytosolic phospholipase A2 activation correlates with HER2 overexpression and mediates estrogen-dependent breast cancer cell growth. |
| Q34757199 | DARPins: an efficient targeting domain for lentiviral vectors |
| Q28830105 | DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer |
| Q47836759 | Deciphering metabolic rewiring in breast cancer subtypes |
| Q64076253 | Detection of (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient Cohort |
| Q100737232 | Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays |
| Q92381716 | Detection of human epidermal growth factor receptor 2 overexpression in canine anal sac gland carcinoma |
| Q38088005 | Developments in single photon emission computed tomography and PET-based HER2 molecular imaging for breast cancer |
| Q41612212 | Dimerization of EGFR and HER2 induces breast cancer cell motility through STAT1-dependent ACTA2 induction. |
| Q38168792 | Discordance and clinical significance of ER, PR, and HER2 status between primary breast cancer and synchronous axillary lymph node metastasis. |
| Q38728221 | Distinct Receptor Tyrosine Kinase Subsets Mediate Anti-HER2 Drug Resistance in Breast Cancer |
| Q54943418 | Dramatic dysbalancing of the Wnt pathway in breast cancers. |
| Q57183898 | Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status |
| Q34130669 | Dual inhibition of both the epidermal growth factor receptor and erbB2 effectively inhibits the promotion of skin tumors during two-stage carcinogenesis. |
| Q33682041 | Dysregulation of Blimp1 transcriptional repressor unleashes p130Cas/ErbB2 breast cancer invasion |
| Q48213081 | EGFR and HER2 activate rigidity sensing only on rigid matrices |
| Q37206247 | EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy |
| Q33878879 | ERBB2 overexpression suppresses stress-induced autophagy and renders ERBB2-induced mammary tumorigenesis independent of monoallelic Becn1 loss |
| Q64095127 | ERBB2-modulated ATG4B and autophagic cell death in human ARPE19 during oxidative stress |
| Q58709253 | Effectiveness of EGFR/HER2-targeted drugs is influenced by the downstream interaction shifts of PTPIP51 in HER2-amplified breast cancer cells |
| Q59333180 | Effects of Modulating Actin Dynamics on HER2 Cancer Cell Motility and Metastasis |
| Q34023669 | Effects of psoralens as anti-tumoral agents in breast cancer cells |
| Q61805419 | Efficacy and safety of targeted therapy for metastatic HER2-positive breast cancer in the first-line treatment: a Bayesian network meta-analysis |
| Q88119092 | Efficacy generated by afatinib in a lung adenocarcinoma patient harboring HER2 S310Y mutation |
| Q36824869 | Efficacy, safety and administration timing of trastuzumab in human epidermal growth factor receptor 2 positive breast cancer patients: A meta-analysis |
| Q38661390 | Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib. |
| Q64258921 | Endoplasmic Reticulum Stress and Unfolded Protein Response in Breast Cancer: The Balance between Apoptosis and Autophagy and Its Role in Drug Resistance |
| Q58106214 | Enrichment of Amplification in Brain Metastases from Primary Gastrointestinal Malignancies |
| Q30412086 | Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models |
| Q47950050 | ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery. |
| Q37330718 | ErbB receptors and cell polarity: new pathways and paradigms for understanding cell migration and invasion |
| Q89886956 | Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-anal |
| Q38083585 | Evaluation of HER2-based biology in 1,006 cases of gastric cancer in a Japanese population |
| Q33585066 | Evolution of costs of cancer drugs in a Portuguese hospital |
| Q38920359 | Evolving Strategies for Target Selection for Antibody-Drug Conjugates |
| Q39172262 | Expression of the Adenovirus Early Gene 1A Transcription-Repression Domain Alone Downregulates HER2 and Results in the Death of Human Breast Cancer Cells Upregulated for the HER2 Proto-Oncogene |
| Q38223605 | Extracellular vesicles shed by glioma cells: pathogenic role and clinical value |
| Q92309451 | FHR4-based immunoconjugates direct complement-dependent cytotoxicity and phagocytosis towards HER2-positive cancer cells |
| Q94594051 | First In-Human Medical Imaging with a PASylated 89Zr-Labeled Anti-HER2 Fab-Fragment in a Patient with Metastatic Breast Cancer |
| Q91980872 | Gene Expression and miRNAs Profiling: Function and Regulation in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer |
| Q38642021 | Gene Signal Distribution and HER2 Amplification in Gastroesophageal Cancer |
| Q45885250 | Gene expression profiling of ErbB receptors and ligands in human meningiomas. |
| Q28590067 | Generation and initial characterization of the prolactin-inducible protein (PIP) null mouse: accompanying global changes in gene expression in the submandibular gland |
| Q55466488 | Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer. |
| Q46668930 | Genes co-amplified with ERBB2 or MET as novel potential cancer-promoting genes in gastric cancer |
| Q37899883 | Genetic determinants of anticancer drug activity: towards a global approach to personalized cancer medicine. |
| Q98465791 | Genome-Wide Profiling of Alternative Splicing Signature Reveals Prognostic Predictor for Esophageal Carcinoma |
| Q35440724 | Genome-wide gene expression profiling of formalin-fixed paraffin-embedded breast cancer core biopsies using microarrays |
| Q42366534 | Genomic alterations in mucins across cancers |
| Q91401487 | Genomic and Therapeutic Landscape of Non-muscle-invasive Bladder Cancer |
| Q37554525 | Global Prioritizing Disease Candidate lncRNAs via a Multi-level Composite Network |
| Q34164930 | Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance |
| Q42378360 | HCaRG/COMMD5 inhibits ErbB receptor-driven renal cell carcinoma |
| Q88669731 | HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3 |
| Q64063349 | HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer |
| Q28078111 | HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists |
| Q38314355 | HER2 assessment by silver in situ hybridization: where are we now? |
| Q28383407 | HER2 confers drug resistance of human breast cancer cells through activation of NRF2 by direct interaction |
| Q91728336 | HER2 gene (ERBB2) amplification is a rare event in non-liver-fluke associated cholangiocarcinogenesis |
| Q57109545 | HER2 inhibition in gastro-oesophageal cancer: A review drawing on lessons learned from breast cancer |
| Q35239611 | HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer |
| Q92093680 | HER2 recruits AKT1 to disrupt STING signalling and suppress antiviral defence and antitumour immunity |
| Q34121631 | HER2/ErbB2-induced breast cancer cell migration and invasion require p120 catenin activation of Rac1 and Cdc42 |
| Q35622862 | HER2: biology, detection, and clinical implications |
| Q37044197 | HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells |
| Q34134476 | Heat-shock transcription factor HSF1 has a critical role in human epidermal growth factor receptor-2-induced cellular transformation and tumorigenesis |
| Q37639917 | Hepatitis B virus X upregulates HuR protein level to stabilize HER2 expression in hepatocellular carcinoma cells. |
| Q54111164 | Her2 Ile655Val polymorphism and its association with breast cancer risk: an updated meta-analysis of case-control studies. |
| Q37257182 | High cell-surface density of HER2 deforms cell membranes |
| Q39664471 | High expression of ErbB2 contributes to cholangiocarcinoma cell invasion and proliferation through AKT/p70S6K |
| Q26750740 | Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going |
| Q34223494 | Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications |
| Q35713259 | IQGAP1 and its binding proteins control diverse biological functions |
| Q24309891 | IQGAP1 protein binds human epidermal growth factor receptor 2 (HER2) and modulates trastuzumab resistance |
| Q92533784 | Identification of an Activating Mutation in the Extracellular Domain of HER2 Conferring Resistance to Pertuzumab |
| Q100425897 | Identifying the worst of the worst: HER2 positive early stage uterine papillary serous carcinoma |
| Q35642359 | Impact of HER-2 overexpression/amplification on the prognosis of gastric cancer patients undergoing resection: a single-center study of 1,036 patients |
| Q39580432 | Impact of protein tyrosine kinase 6 (PTK6) on human epidermal growth factor receptor (HER) signalling in breast cancer. |
| Q39802740 | Impaired PTPN13 phosphatase activity in spontaneous or HPV-induced squamous cell carcinomas potentiates oncogene signaling through the MAP kinase pathway |
| Q40745788 | Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain |
| Q38818802 | Improved therapeutic activity of HER2 Affibody-targeted cisplatin liposomes in HER2-expressing breast tumor models. |
| Q35140953 | In vivo molecular imaging of HER2 expression in a rat model of Barrett's esophagus adenocarcinoma. |
| Q34129444 | Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study |
| Q38903044 | Induction of fibronectin by HER2 overexpression triggers adhesion and invasion of breast cancer cells. |
| Q35952745 | Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancers |
| Q42711780 | Interaction of marine Streptomyces compounds with selected cancer drug target proteins by in silico molecular docking studies |
| Q89993110 | Interleukin-6 is required for Neuregulin-1 induced HER2 signaling in lung epithelium |
| Q47156322 | Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy. |
| Q35633666 | Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification |
| Q52618828 | Intratumoral Heterogeneity of ERBB2 Amplification and HER2 Expression in Micropapillary Urothelial Carcinoma. |
| Q54361340 | Inverse prognostic impact of ErbB2 mRNA and protein expression level in tumors of soft tissue sarcoma patients. |
| Q33627215 | Investigating AP-2 and YY1 protein expression as a cause of high HER2 gene transcription in breast cancers with discordant HER2 gene amplification |
| Q50875570 | Investigation of the role of DNA methylation in the expression of ERBB2 in human myocardium. |
| Q39202214 | LC-MS/MS Validation Analysis of Trastuzumab Using dSIL Approach for Evaluating Pharmacokinetics. |
| Q33378824 | Leptin/HER2 crosstalk in breast cancer: in vitro study and preliminary in vivo analysis |
| Q64091958 | Loss of Nuclear ARID-1A Expressions Is Associated with Hormone Receptor Status in Breast Cancers |
| Q34622404 | MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway |
| Q33909073 | MUC13 mucin augments pancreatic tumorigenesis |
| Q24630950 | MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells |
| Q59129055 | Machine Learning With K-Means Dimensional Reduction for Predicting Survival Outcomes in Patients With Breast Cancer |
| Q36630091 | Malignant peripheral nerve sheath tumor invasion requires aberrantly expressed EGF receptors and is variably enhanced by multiple EGF family ligands. |
| Q37671920 | Mechanisms of resistance to HER family targeting antibodies |
| Q33965342 | Mechanistic and signaling analysis of Muc4-ErbB2 signaling module: new insights into the mechanism of ligand-independent ErbB2 activity. |
| Q46214152 | Membrane Mucin Muc4 promotes blood cell association with tumor cells and mediates efficient metastasis in a mouse model of breast cancer |
| Q59803127 | Metastatic Colorectal Cancer in the Era of Personalized Medicine: A More Tailored Approach to Systemic Therapy |
| Q27306870 | Methylsulfonylmethane suppresses breast cancer growth by down-regulating STAT3 and STAT5b pathways |
| Q28072513 | Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer |
| Q64921722 | Molecular docking analysis of Cianidanol fromGinkgo biloba with HER2+ breast cancer target. |
| Q37633179 | Molecular imaging of breast cancer. |
| Q38444869 | Molecular imaging using PET for breast cancer |
| Q38562599 | Molecular imaging-its current role in cancer |
| Q39259280 | Mollugin inhibits proliferation and induces apoptosis by suppressing fatty acid synthase in HER2-overexpressing cancer cells |
| Q40001089 | Multipathway model enables prediction of kinase inhibitor cross-talk effects on migration of Her2-overexpressing mammary epithelial cells |
| Q89981757 | Mutation signatures to Pan-Cancer Atlas: Investigation of the genomic landscape of muscle-invasive bladder cancer |
| Q38744598 | Mycophenolic acid potentiates HER2-overexpressing SKBR3 breast cancer cell line to induce apoptosis: involvement of AKT/FOXO1 and JAK2/STAT3 pathways |
| Q91933716 | Nectin-4 cis-interacts with ErbB2 and its trastuzumab-resistant splice variants, enhancing their activation and DNA synthesis |
| Q37037781 | Negative Selection and Chromosome Instability Induced by Mad2 Overexpression Delay Breast Cancer but Facilitate Oncogene-Independent Outgrowth |
| Q64981225 | Neoadjuvant zoledronic acid for HER2-positive breast cancer: the Zo-NAnTax trial. |
| Q98158105 | Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial |
| Q48205560 | Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies |
| Q95273167 | Novel antibody-drug conjugates for triple negative breast cancer |
| Q41608170 | Oncogene Knockdown via Active Loading of Small RNAs into Extracellular Vesicles by Sonication |
| Q38935156 | Oncogenic and tumor-suppressive mouse models for breast cancer engaging HER2/neu |
| Q34226408 | Optical fiber-based in vivo quantification of growth factor receptors |
| Q35784634 | Optical imaging with her2-targeted affibody molecules can monitor hsp90 treatment response in a breast cancer xenograft mouse model |
| Q34064466 | Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma |
| Q54399364 | Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome. |
| Q51741363 | Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance. |
| Q33557258 | Overexpression of the HER2/neu Gene: A New Therapeutic Possibility for Patients With Advanced Gallbladder Cancer |
| Q29615530 | PI3K pathway alterations in cancer: variations on a theme |
| Q35217174 | PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis |
| Q34663927 | Paclitaxel-induced apoptosis is BAK-dependent, but BAX and BIM-independent in breast tumor |
| Q36941519 | Pak1 kinase links ErbB2 to β-catenin in transformation of breast epithelial cells |
| Q91719970 | Peptide-Based Vaccines: Current Progress and Future Challenges |
| Q37750891 | Pertuzumab for the treatment of ovarian cancer. |
| Q38861026 | Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations |
| Q36289916 | Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer |
| Q36245418 | Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells. |
| Q55286461 | Polyethylene glycol-conjugated HER2-targeted peptides as a nuclear imaging probe for HER2-overexpressed gastric cancer detection in vivo. |
| Q35602561 | Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models. |
| Q91646711 | Potent Antitumor Activity of Liposomal Irinotecan in an Organoid- and CRISPR-Cas9-Based Murine Model of Gallbladder Cancer |
| Q38838757 | Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment |
| Q35051651 | Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2 |
| Q27012540 | Profile of neratinib and its potential in the treatment of breast cancer |
| Q37222927 | Prognostic Value of Invasion, Markers of Proliferation, and Classification of Giant Pituitary Tumors, in a Georeferred Cohort in Brazil of 50 Patients, with a Long-Term Postoperative Follow-Up |
| Q53316293 | Prognostic significance of HER2 expression in neuroblastic tumors. |
| Q41577682 | Prognostic significance of the co-expression of EGFR and HER2 in adenocarcinoma of the uterine cervix. |
| Q47261659 | Protein biomarkers for subtyping breast cancer and implications for future research. |
| Q55715013 | Quantification of Circulating Cancer Biomarkers via Sensitive Topographic Measurements on Single Binder Nanoarrays. |
| Q47134627 | Quantitative, in situ analysis of mRNAs and proteins with subcellular resolution. |
| Q36814396 | Quantum dots for cancer research: current status, remaining issues, and future perspectives |
| Q37992923 | Quantum dots hold promise for early cancer imaging and detection |
| Q34408090 | Reciprocal regulation of annexin A2 and EGFR with Her-2 in Her-2 negative and herceptin-resistant breast cancer |
| Q64279990 | Recognition of HER2 expression in hepatocellular carcinoma and its significance in postoperative tumor recurrence |
| Q30419961 | Reduced androgen receptor expression accelerates the onset of ERBB2 induced breast tumors in female mice |
| Q33671632 | Reduction of miR‑132‑3p contributes to gastric cancer proliferation by targeting MUC13. |
| Q55261836 | Relationship Between ADAMTS8, ADAMTS18, and ADAMTS20 (A Disintegrin and Metalloproteinase with Thrombospondin Motifs) Expressions and Tumor Molecular Classification, Clinical Pathological Parameters, and Prognosis in Breast Invasive Ductal Carcinoma |
| Q34551761 | Resiliency and vulnerability in the HER2-HER3 tumorigenic driver |
| Q35591518 | Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications |
| Q36318226 | Resistance to Trastuzumab in Breast Cancer. |
| Q55178886 | Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification. |
| Q30838103 | Role of YY1 in the pathogenesis of prostate cancer and correlation with bioinformatic data sets of gene expression |
| Q38889500 | Role of cannabinoid receptor CB2 in HER2 pro-oncogenic signaling in breast cancer |
| Q37459311 | S100A14, a member of the EF-hand calcium-binding proteins, is overexpressed in breast cancer and acts as a modulator of HER2 signaling |
| Q36934463 | SGK3 is associated with estrogen receptor expression in breast cancer |
| Q37004743 | Selective Raf inhibition in cancer therapy |
| Q38857859 | Sensitization of HER2 Positive Breast Cancer Cells to Lapatinib Using Plants-Derived Isothiocyanates |
| Q45234395 | Significance of epidermal growth factor receptor expression in breast cancer |
| Q49922621 | Simulated ablation for detection of cells impacting paracrine signalling in histology analysis |
| Q64058873 | Single-Chain Variable Fragment-Based Bispecific Antibodies: Hitting Two Targets with One Sophisticated Arrow |
| Q37138610 | Small nucleolar RNA 42 acts as an oncogene in lung tumorigenesis |
| Q24293655 | Spontaneous and pronase-induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell lines |
| Q93006248 | Structure-Activity Relationship of HER2 Receptor Targeting Peptide and Its Derivatives in Targeted Tumor Therapy |
| Q36689047 | Suppression of tumor angiogenesis by metformin treatment via a mechanism linked to targeting of HER2/HIF-1α/VEGF secretion axis |
| Q58728275 | Synergistic Targeting HER2 and EGFR with Bivalent Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth |
| Q55317203 | Synergistic antitumor activity by combining trastuzumab with retinoic acid in HER2 positive human breast cancer cells. |
| Q48158060 | Synergistic effect of a novel autophagy inhibitor and Quizartinib enhances cancer cell death |
| Q58616181 | Systematic analysis of breast atypical hyperplasia-associated hub genes and pathways based on text mining |
| Q98164379 | Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence |
| Q36544237 | Targeting EMP3 suppresses proliferation and invasion of hepatocellular carcinoma cells through inactivation of PI3K/Akt pathway |
| Q99408604 | Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications |
| Q36898642 | Targeting HER proteins in cancer therapy and the role of the non-target HER3. |
| Q38632768 | Targeting HER2 in Advanced Breast Cancer |
| Q49700421 | Targeting HER2 in Nuclear Medicine for Imaging and Therapy |
| Q48234912 | Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3. |
| Q51060657 | Targeting of EGFR and HER2 with therapeutic antibodies and siRNA: a comparative study in glioblastoma cells. |
| Q34766486 | Targeting the function of the HER2 oncogene in human cancer therapeutics |
| Q34424285 | Testing for HER2 in Breast Cancer: A Continuing Evolution |
| Q49544424 | The Dawning of Translational Breast Cancer: From Bench to Bedside |
| Q64072053 | The Endocannabinoid System as a Target in Cancer Diseases: Are We There Yet? |
| Q34558080 | The HER family and cancer: emerging molecular mechanisms and therapeutic targets |
| Q36780754 | The HER2- and heregulin β1 (HRG)-inducible TNFR superfamily member Fn14 promotes HRG-driven breast cancer cell migration, invasion, and MMP9 expression |
| Q33609935 | The HER2-encoded miR-4728-3p regulates ESR1 through a non-canonical internal seed interaction |
| Q58581282 | The Importance of the Right Framework: Mitogen-Activated Protein Kinase Pathway and the Scaffolding Protein PTPIP51 |
| Q36466104 | The Metastasis Suppressor, N-MYC Downstream-regulated Gene-1 (NDRG1), Down-regulates the ErbB Family of Receptors to Inhibit Downstream Oncogenic Signaling Pathways |
| Q90682184 | The Mutational Landscape of Pancreatic and Liver Cancers, as Represented by Circulating Tumor DNA |
| Q42498482 | The P-Rex1/Rac signaling pathway as a point of convergence for HER/ErbB receptor and GPCR responses |
| Q99712042 | The Role of HER2 in Self-Renewal, Invasion, and Tumorigenicity of Gastric Cancer Stem Cells |
| Q30446768 | The biology of malignant breast tumors has an impact on the presentation in ultrasound: an analysis of 315 cases |
| Q34363400 | The epidermal growth factor receptor family in breast cancer |
| Q93012400 | The expression of the long NEAT1_2 isoform is associated with human epidermal growth factor receptor 2-positive breast cancers |
| Q37688976 | The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer |
| Q37802557 | The molecular physiology of nuclear retinoic acid receptors. From health to disease |
| Q34185812 | The mucin MUC4 and its membrane partner ErbB2 regulate biological properties of human CAPAN-2 pancreatic cancer cells via different signalling pathways |
| Q35793641 | The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2. |
| Q38254375 | The potential for targeting HER2 therapeutically in esophageal cancer - a grasp at straws? |
| Q37319323 | The potential role of HER2 upregulation in metastatic breast cancer to the uterus: a case report |
| Q37270446 | The role of PTEN signaling perturbations in cancer and in targeted therapy |
| Q34578129 | The role of n-3 polyunsaturated fatty acids in the prevention and treatment of breast cancer |
| Q55033826 | The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients. |
| Q48325287 | Timing of the negative effects of trastuzumab on cardiac mechanics after anthracycline chemotherapy |
| Q91974174 | Towards personalized treatment for early stage HER2-positive breast cancer |
| Q92191529 | Traditional and Novel Mechanisms of Heat Shock Protein 90 (HSP90) Inhibition in Cancer Chemotherapy Including HSP90 Cleavage |
| Q34950377 | Transforming Properties of 8p11-12 Amplified Genes in Human Breast Cancer |
| Q102075298 | Transient commensal clonal interactions can drive tumor metastasis |
| Q46720677 | Translational nanoparticle engineering for cancer vaccines. |
| Q84244714 | Trastuzumab |
| Q27851975 | Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors |
| Q30458767 | Treatment of vestibular schwannoma cells with ErbB inhibitors |
| Q52780137 | Trial Watch: Adoptively transferred cells for anticancer immunotherapy. |
| Q55249964 | Triple-negative invasive breast carcinoma: the association between the sonographic appearances with clinicopathological feature. |
| Q37990333 | Tristetraprolin: roles in cancer and senescence |
| Q36544650 | Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor |
| Q36629452 | Tunicamycin enhances the antitumor activity of trastuzumab on breast cancer in vitro and in vivo |
| Q35895143 | Two dimensions in targeting HER2. |
| Q35811043 | Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells |
| Q50965396 | Urinary titanium and vanadium and breast cancer: a case-control study. |
| Q38731617 | Variability in Platelet-Derived Growth Factor Receptor Alpha Antibody Specificity May Impact Clinical Utility of Immunohistochemistry Assays |
| Q93377635 | Y-Box binding protein 1 expression in breast cancer and its correlation with hormone receptors and other prognostic markers |
| Q39093109 | c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer. |
| Q38873436 | miRNA-150 downregulation promotes pertuzumab resistance in ovarian cancer cells via AKT activation |
| Q37421359 | t10,c12-Conjugated linoleic acid stimulates mammary tumor progression in Her2/ErbB2 mice through activation of both proliferative and survival pathways |
Search more.